This prospective, observational cohort study evaluates patient-reported outcomes (PRO’s) in patients initiating GLP-1 RA therapy in a real-world setting. Patients with type 2 diabetes initiating GLP-1 RA therapy as part of their usual treatment approach were enrolled from Ontario-based LMC Diabetes and Endocrinology clinics. Patients completed questionnaires assessing medication and device satisfaction and medication adherence at baseline and at follow-up (3-6 months). Standard clinical outcomes were collected. To date, 320 subjects have been enrolled: 187 dulaglutide (DULA), 110 liraglutide (LIRA), and 23 switching from LIRA to DULA. At baseline, PRO’s and clinical measures were similar between cohorts (mean age 54.2 ± 10.1 years; mean HbA1c 8.4 ± 1.5%). In this interim analysis of 110 completers to date (mean follow-up 3.3 months), there was a trend for the 77 DULA completers to have greater improvements in PRO scores compared to the 33 LIRA completers (Figure). To-date, DULA subjects had a 1.1 ± 1.0% reduction in HbA1c and 2.2 ± 3.3 kg reduction in weight. The LIRA subjects showed similar trends (1.2 ± 1.0% reduction in HbA1c and 2.4 ± 3.2 kg reduction in weight). Interim analysis of this real-world, specialist-led registry of patients initiating GLP-1 RA therapy showed similar improvements in PRO’s and clinical outcomes.

graphic
View largeDownload slide
Disclosure

R.E. Brown: None. A. Abitbol: Research Support; Self; JDRF, JA DeSeve Foundation, Lexicon Pharmaceuticals, Inc., Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; GlaxoSmithKline plc., Merck & Co., Inc.. Consultant; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Research Support; Self; Pfizer Inc., AstraZeneca. Consultant; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; Senseonics, Gilead Sciences, Inc.. Speaker's Bureau; Self; Amgen Inc., Janssen Pharmaceuticals, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc.. Employee; Self; LMC Diabetes & Endocrinology. Speaker's Bureau; Self; LMC Diabetes & Endocrinology, Valeant Pharmaceuticals International, Inc.. Consultant; Self; Valeant Pharmaceuticals International, Inc. H.S. Bajaj: Speaker's Bureau; Self; Abbott. Advisory Panel; Self; Amgen Inc.. Speaker's Bureau; Self; Amgen Inc.. Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca, Bayer AG. Advisory Panel; Self; Boehringer Ingelheim GmbH. Research Support; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., Medtronic. Advisory Panel; Self; Merck & Co., Inc.. Research Support; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc., Mylan. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Valeant Pharmaceuticals International, Inc.. Research Support; Self; Valeant Pharmaceuticals International, Inc.. Speaker's Bureau; Self; Valeant Pharmaceuticals International, Inc. H. Khandwala: Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Novo Nordisk Inc., AstraZeneca. Advisory Panel; Self; Sanofi, Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Other Relationship; Self; Amgen Inc.. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. R. Goldenberg: Advisory Panel; Self; Abbott, Amgen Inc., AstraZeneca. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Servier. Advisory Panel; Self; Merck & Co., Inc.. S. Abdel-Salam: None. R. Aronson: Other Relationship; Self; Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Sanofi, AstraZeneca. Research Support; Self; Eli Lilly and Company, Becton, Dickinson and Company, Merck & Co., Inc., Senseonics, Boehringer Ingelheim Pharmaceuticals, Inc..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.